Drug
Efavaleukin Alfa
Efavaleukin Alfa: highest development phase Phase 1/2, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efavaleukin alfa NCT03410056 | Phase 1/2 | Rheumatoid Arthritis RA |
Latest
No recent events.
Follow Efavaleukin Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.